neupogenhcp.com
Chemotherapy-Induced Neutropenia and G-CSF
http://www.neupogenhcp.com/chemotherapy-induced-neutropenia
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. Daily NEUPOGEN decreased the duration of chemotherapy-induced neutropenia. Chemotherapy-induced nadir occurred earlier with NEUPOGEN (filgrastim) therapy. Duration and depth of chemotherapy-induced neutropenia and associated nadir. Who were randomized to receive either placebo (n=111) or NEUPOGEN (n=99) 24 hours. In which case growth factor was discontinued for the remainder of the cycle). Filgrastim) P...
neupogenhcp.com
NEUPOGEN® (filgrastim) Important Safety Information
http://www.neupogenhcp.com/important-safety-information
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN (filgrastim): Important Safety Information and Indications. Important Safety Information and Indications. Is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony stimulating factors, such as filgrastim or pegfilgrastim. Splenic rupture, including fatal cases, has been reported following the administration of NEUPOGEN. In patients with ARDS. Glomer...
neupogenhcp.com
Febrile Neutropenia (FN)
http://www.neupogenhcp.com/febrile-neutropenia
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN (filgrastim) indication: febrile neutropenia (FN). Patients with cancer receiving myelosuppressive chemotherapy. NEUPOGEN is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. After the expected nadir.
neupogenhcp.com
NEUPOGEN® (filgrastim) Support Materials
http://www.neupogenhcp.com/support-materials
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN (filgrastim) support materials for physicians and patients. Below you will find NEUPOGEN (filgrastim) brochures, links and an app download for your practice. Summarizes the packaging options for NEUPOGEN administration, for both vials and pre-filled syringes. NEUPOGEN Dosing Resource Guide. Useful links for healthcare professionals. Get more information at http:/ www.cancer.gov. This organizati...
neupogenhcp.com
Amgen Resources
http://www.neupogenhcp.com/resources
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. Amgen: commitment, passion, and a drive for patient care. From innovative research and therapies to patient support programs, Amgen is helping to make a difference. A pioneer in biotechnology, with 30 years of experience in the research, development, and manufacturing of complex biologic therapies. Dedicated to reliably supplying medicines to patients. Take a Virtual Tour. A legacy of innovation. Evalua...
neupogenhcp.com
NEUPOGEN® (filgrastim) Duration of Therapy and Dosing
http://www.neupogenhcp.com/duration-and-dosing
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. Appropriate dosing of NEUPOGEN (filgrastim) helps reduce the incidence of febrile neutropenia. NEUPOGEN used for 7 days had a lower incidence of febrile neutropenia compared with dosing of. Data obtained through review of patient medical records for the Oncology Practice Pattern Study at 12 sites between 1991 and 1999. Study included patients (n = 170). Scott SD, et al. J Manag Care Pharm. Acute Respira...
neupogenhcp.com
NEUPOGEN® (filgrastim) Administration Options
http://www.neupogenhcp.com/neupogen-administration
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN administration options: the only G-CSF available in vials and prefilled syringes. NEUPOGEN (filgrastim) packaging options. 1 syringe SINGLE PACK. 300 mcg/0.5 mL (600 mcg/mL) single-use syringe. 1 syringe SINGLE PACK. 480 mcg/0.8 mL (600 mcg/mL) single-use syringe. 300 mcg/0.5 mL (600 mcg/mL) single-use syringe. 480 mcg/0.8 mL (600 mcg/mL) single-use syringe. REVIEW THE CLINICAL DATA. Evaluate p...
neupogenhcp.com
About NEUPOGEN® (filgrastim) | G-CSF Injection
http://www.neupogenhcp.com/g-csf
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN (filgrastim) was the first FDA-approved granulocyte colony-stimulating. NEUPOGEN has a strong heritage. Amgen has been a pioneer in developing and delivering G-CSF therapy and launched NEUPOGEN in 1991. Human G-CSF produced by recombinant DNA technology. Elimination half-life: approximately 3.5 hours. Details on indication-specific dosing. Available in single-dose syringes and vials. Splenic ru...
neupogenhcp.com
Patients with Acute Myeloid Leukemia (AML) Receiving Induction or Consolidation Chemotherapy
http://www.neupogenhcp.com/acute-myeloid-leukemia
For the following patient populations:. Peripheral Blood Progenitor Cell. Effect on Neutrophil Levels. NEUPOGEN (filgrastim) indication: acute myeloid leukemia (AML). Patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy. NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). Recommended dosing and administration. L for 3 ...
SOCIAL ENGAGEMENT